Please login to the form below
Valeant
The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Valeant's Japan sales performance.
AbbVie lauds head-to-head win for Skyrizi versus Cosentyx
Cosentyx, Skyrizi and Tremfya face increasing competition in the psoriasis market however, with a host of other new entrants including Eli Lilly’s Taltz (ixekizumab), Leo/Valeant’s Siliq (brodalumab) and
Shire bags US approval for constipation drug Motegrity
Bausch Health (formerly Valeant) has just launched a bid for the company on the premise that it will be able to kick start sales of Trulance, Synergy’s only-approved product,
J&J takes on Novartis’ Cosentyx with head-to-head psoriasis trial
Cosentyx was the first IL-17 inhibitor to reach the market and, while it has since been joined by rivals from Eli Lilly (Taltz) and Valeant (Siliq), is well ahead in
Daily Brief: Andrew Witty's replacement on Accelerated Access initiative, Blincyto gains full EU approval and more
Valeant shares tumble after FDA rejection. A rejection by the US regulator for Valeant’s plaque psoriasis treatment. ... Valeant said in a statement that the FDA had not specified any clinical efficacy or safety shortcomings in its Complete Response
UK, Germany back routine use of J&J’s Tremfya
Add in additional IL-17 inhibitors for Eli Lilly and Valeant and the market for biologics for psoriasis is looking increasingly crowded, and a lot will depend on which of the
Data provided by GlobalData
GlobalData is the premier source of research and consulting solutions for the pharmaceutical and medical device industries. With the combined expertise of more than 600 researchers, market analysts and consultants, we deliver high-quality, accurate and transparent industry insight that helps our clients to achieve growth and increase business value.
To find out more about how our research and consulting solutions can help you, please visit healthcare.globaldata.com
For more details on the data and methodology used to create the Top Pharma Lists, please visit PMLiVE's Top Pharma List - Methodology
COVID-19 Updates and Daily News
Featured jobs
- EMA clears BMS’ oral multiple sclerosis drug Zeposia
- Biogen delays filing of Alzheimer’s drug, which hits its share price
- EMA clears BMS’ oral multiple sclerosis drug Zeposia
- Alnylam and Vir plan gene-silencing attack on COVID-19 virus
- Merck’s Keytruda hits the mark in triple negative breast cancer
- Finalists 2020 - Communiqué Awards
- ASCO: Momentum gathers behind next wave of CAR-T therapies
- Lilly starts world first trial of an antibody drug for COVID-19
- Pfizer’s Ibrance misses the mark in early breast cancer
- Rise of the patient influencer
- Working together against COVID-19
- Vicky Bramham, Managing Director at OPEN Health PR shares tips on media relations during COVID-19
PMHub
Page & Page
For those who can imagine better, Page & Page is home to meaningful encounters of a marketing, communication and creative kind:...
Latest intelligence
- Working together against COVID-19
- Analysing social media conversations to see what HCPs are saying online about the global pandemic...
- Vicky Bramham, Managing Director at OPEN Health PR shares tips on media relations during COVID-19
- Vicky speaks with freelance health journalist Jacqui Thornton who gives her expert view on how best to approach media relations during this unprecedented time....
- Are biobetters a market access opportunity?
- Biobetters are biologics that have been improved compared to the marketed originator, for example in efficacy, safety, tolerability or dosing regimen....
Quick links
Infographics
